Real-time clinical trials could accelerate drug development, but raise new questions on trust, bias and who controls the narrative.
An assumption baked into modern medicine is that by the time regulators see clinical trial data, it has already been cleaned, checked and carefully arranged into a story that makes sense. The US Food and Drug Administration (FDA) is now challenging that assumption.
In a move that could reshape how drugs are tested and approved, the agency has announced early steps toward real-time clinical trials, an approach where data flows directly to regulators as it is generated, not months later after layers of processing [1].
“For 60 years, we’ve been conducting clinical trials in the same way, where key data signals can take years to reach the FDA,” said Commissioner Marty Makary. “We are boldly advancing a modern approach whereby FDA scientists can view safety signals and endpoints in real time as a trial progresses.”
It sounds almost obvious when you say it out loud: why wait for the full report when you can watch the story unfold? However, that simple shift – watching instead of waiting – changes more than just timelines.
Traditional clinical trials work like photography. You take thousands of snapshots, then spend months editing them into a final album. Only then do regulators get to see the pictures. Real-time trials turn that into a live stream.
Instead of a polished dataset, the FDA gets a continuous feed – messy, incomplete and evolving. The agency has already begun testing this model through proof-of-concept studies led by AstraZeneca and Amgen, showing that the technical side of real-time data sharing is, at least, possible.
The promise is speed. Faster detection of safety signals. Faster decisions on whether a drug is working. Potentially, faster access for patients waiting on treatments that could change (or extend) their lives.
For longevity science, where the clock is always ticking, that promise carries weight. A therapy that arrives even a year earlier can mean the difference between prevention and progression.
But speed has a way of exposing everything else. One of the most immediate concerns raised by industry experts is something simple: the data might not be ready. In today’s system, data cleaning is not a side step; it’s the step. It’s where inconsistencies are resolved, errors are corrected and context is added. Without it, numbers can mislead as easily as they inform.
Susan Stewart, a chief regulatory officer of California-based biopharma Rezolute, Inc, captured the unease in a comment in Makary’s LinkedIn post: “Where is the step where the data FDA is seeing has been monitored and cleaned first?” It’s a fair question. Real-time access could mean regulators are looking at what insiders sometimes call “dirty data,” raw inputs that haven’t yet been validated.
Imagine trying to judge a film based on behind-the-scenes footage rather than the final cut. You might see brilliance early but also confusion, false starts and scenes that never make it to the end.
There’s also the issue of bias, which doesn’t vanish in real time; it just arrives sooner. Sharon Bathory, a pharmacovigilance leader at SpringWorks Therapeutics, pointed to a subtle but critical challenge: whether real-time data streams will be blinded or unblinded. In clinical trials, blinding helps prevent researchers from unconsciously influencing outcomes. Remove or weaken that, and interpretation becomes more fragile.
At the same time, continuous visibility could create pressure to act too quickly. When data is always available, the temptation is to always respond, even when waiting might lead to better decisions. The tension between urgency and restraint may define how successful real-time trials ultimately become.
Beyond the technical hurdles lies a deeper shift: control. Now, who owns the story? Clinical trials have long been structured around clear roles. Sponsors generate and analyze data. Regulators review it. Each step is sequential, deliberate and documented.
Real-time trials blur those boundaries. If regulators are watching data as it emerges, they are no longer just reviewers; they become, in some sense, participants in the process. That raises new questions about responsibility, interpretation and even accountability.
Wijdan Suliman, founder of HolistiNova Research, highlighted another layer: decision-making itself. In a real-time environment, it’s not enough to know what decision was made. You need to know why, in the moment it was made. That kind of “decision traceability” is still an emerging capability. Many systems can track data. Far fewer can track reasoning.
Despite the friction, the direction of travel feels clear. “Moving toward real-time clinical trials has the potential to fundamentally shift how evidence is generated, evaluated and acted on,” said Chanille Juneau, Chief Product and Technology Officer at Accumulus Technologies.
In longevity, that shift could be especially profound. Aging is not a single disease but a slow, complex process unfolding over time. Studying it requires long horizons, nuanced data and careful interpretation. Real-time trials could compress parts of that process, allowing researchers to adjust, iterate and learn faster.
However, they also raise the stakes. When you’re dealing with interventions that aim to extend healthspan or lifespan, the cost of getting it wrong isn’t just regulatory; it’s deeply human.
The FDA’s announcement is an opening move. A Request for Information signals that the agency is still seeking industry input on how this should work, not dictating a final answer. That may be the most important detail. Real-time trials are a cultural shift in how medicine handles uncertainty, speed and trust.
Done well, they could shorten the distance between discovery and delivery, bringing longevity-focused therapies to patients faster than ever before. Done poorly, they risk replacing one bottleneck with another, swapping slow certainty for fast ambiguity.
For now, the live stream has just begun. The question is whether the system watching it is ready to keep up.
